CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Generic Name||Inotuzumab Ozogamicin|
|Indication||Acute Lymphoblastic Leukemia (ALL)|
|Funding Request||For the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)|
|Pre Noc Submission||Yes|
|NOC Date||March 15, 2018|
|Manufacturer||Pfizer Canada Inc.|
|Sponsor||Pfizer Canada Inc.|
|Submission Date||November 13, 2017|
|Submission Deemed Complete||November 20, 2017|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||November 27, 2017|
|Check-point meeting||January 25, 2018|
|pERC Meeting||April 19, 2018|
|Initial Recommendation Issued||May 3, 2018|
|Feedback Deadline ‡||May 17, 2018|
|pERC Reconsideration Meeting||June 21, 2018|
|Final Recommendation Issued||July 6, 2018|
|Notification to Implement Issued||July 23, 2018|
|Therapeutic Area||Acute Lymphoblastic Leukemia (ALL)|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.